A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation studyJesse J. Swen, Roelof Bosch, Magnus Ingelman‐Sundberg et al.|The Lancet|2023Cited by 508
Human genetic factors associated with susceptibility to SARS-CoV-2 infection and COVID-19 disease severityCleo Anastassopoulou, Athanasios Tsakris, Zoi Gkizarioti et al.|Human Genomics|2020Cited by 213
Economic evaluation in psychiatric pharmacogenomics: a systematic reviewKariofyllis Karamperis, Christina Mitropoulou, Maria Koromina et al.|The Pharmacogenomics Journal|2021Cited by 59
Clinical implementation of preemptive pharmacogenomics in psychiatryΜαρία Σκώκου, Athanassios Vozikis, Kariofyllis Karamperis et al.|EBioMedicine|2024Cited by 56
Leukocyte telomere length is reduced in patients with major depressive disorderClaudia Pisanu, Alessio Squassina, Evangelia Eirini Tsermpini et al.|Drug Development Research|2019Cited by 25